LBB Specialties Enters into Strategic Partnership for Excipient Product Distribution

Article

LBB Specialties and Meggle Excipients & Technology will work to distribute excipient products to companies in the American pharmaceutical and nutraceutical industries.

LeBaronBrown Specialties (LBB), a North American specialty chemical and ingredients distribution company, announced it entered into a strategic partnership on Aug. 1, 2019 with Meggle Excipients & Technology, a Wasserburg, Germany-based holding company in the dairy industry, to distribute its excipient products to companies in the American pharmaceutical and nutraceutical industries. 

American International Chemical (AIC) and Charkit Chemical Company, LBB Specialties’ subsidiary companies, will handle the sales, marketing, and distribution efforts for Meggle products in the US market, according to an Aug. 27, 2019 press release. 

Meggle provides the pharmaceutical industry with lactose-based excipients for direct compression and granulation tableting, powder preparations, and dry powder inhalation while investing sufficiently in R&D.

“Representing [Meggle] is a tremendous addition for Charkit and AIC,” said Jay Lang, president of Charkit Chemical, in the press release. “[Meggle] is one of only a handful of manufacturers of pharma-grade lactose excipients in the world, and they are well known for the excellent quality of their product portfolio, including value-added excipients for direct compression and inhalation applications.”

“The industry knowledge, customer focus, and broad-based capabilities offered by Charkit and AIC make them excellent partners for [Meggle],” said Ruth Leinenbach, director, BG Excipients and Technology at Meggle, in the press release. “The combination of our technical knowledge and the professional sales expertise of our new partners is a powerful recipe for success.”

Source: LBB Specialties 

 

Recent Videos
Behind the Headlines episode 5
Lee Cronin, founder and CEO of Chemify
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.